Key facts
- This page summarizes Tighe Reardon's Form 4 filing for Janux Therapeutics, Inc. (JANX).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 05 Jun 2024, 19:23.
Tighe Reardon - 03 Jun 2024 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)
- Reporting relationship
- Acting Chief Financial Officer
- Issuer ticker
- JANX
- Reported as of
- 03 Jun 2024
- Net transaction value
- -$45,043,975
- SEC form
- 4
- Accepted by SEC
- 05 Jun 2024, 19:23:19 UTC
- Prior SEC filing
- 03 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Tighe Reardon
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Tighe Reardon filed Form 4 for Janux Therapeutics, Inc. (JANX) on 05 Jun 2024.
Change
- Previous filing in this sequence was filed on 03 Jan 2024.
- Current net transaction value: -$45,043,975.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
JANX
transaction
Common Stock
Sale
- Transaction value
- $7,182,981
- Shares
- -131,196
- Change %
- -17%
- Price
- $54.75
- Shares after
- 633,673
- Date
- 03 Jun 2024
- Ownership
- By Avalon BioVentures I, LP
- Footnotes
- F1, F2
JANX
transaction
Common Stock
Sale
- Transaction value
- $37,860,994
- Shares
- -691,525
- Change %
- -17%
- Price
- $54.75
- Shares after
- 3,340,018
- Date
- 03 Jun 2024
- Ownership
- By Avalon BioVentures SPV I, L.P.
- Footnotes
- F1, F3
JANX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 174,989
- Date
- 03 Jun 2024
- Ownership
- Direct
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.75 to $55.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F2
The shares are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is a general partner of ABV I and may be deemed to have voting and investment power with respect to the shares held by ABV I and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is a managing member of ABV GP and shares voting and investment power with respect to the shares held by ABV I. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any.
Footnote F3
The shares are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is a managing member of ABV SPV GP and shares voting and investment power with respect to the shares held by ABV SPV. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any.
Footnote F4
The shares held directly by the Reporting Person prior to the transactions reported herein reflect the receipt of shares pursuant to the pro rata distributions in kind, effected by each of ABV I and ABV SPV to its general partner and limited partners for no additional consideration, and the further pro rata distribution in kind by the general partners of ABV I and ABV SPV, for no additional consideration to their members, including the Reporting Person. The receipt of such shares by the Reporting Person constituted a change in form of ownership from indirect to direct, which was exempt from reporting pursuant to Rule 16a-13.